There is a method for selective translation of a desired protein. The method has the steps of (a) providing two half cores of a deoxyribozyme, wherein each half core includes a pendant assembly arm of a strand of nucleic acids extending therefrom and a separate, pendant binding arm extending therefrom of a strand of nucleic acids; (b) binding a nucleic acid ligand to each of the two assembly arms to form an intermediate; (c) binding the intermediate to (i) a first substrate of ribonucleic acid sequences capped at one end, (ii) a second substrate of a strand of ribonucleic acids having a 5 triphosphate region at one end and a region of polyadenylated nucleotides at the other end and wherein the second substrate codes for the desired protein, (iii) join the two half cores to form a core in order to form a ligated product; and (d) allowing the translation for the desired protein to proceed from the ligated product. There is another method for selective translation of a desired protein. There is also a modified nucleic acid enzyme.

The present invention relates generally to a method of treating a neoplastic condition. More particularly, the present invention is directed to a method of selectively sensitising neoplastic cells prior to chemotherapy. The method of the present invention is predicated on administering chemotherapy treatment subsequently to neoplastic cell sensitisation via the exposure of these cells to an activin type 1 B receptor (ACVR1B) antagonist. The present findings have now enabled the development of a new neoplastic treatment regime exhibiting both higher efficacy and reduced side effects for patients and, still further, a means of effectively treating chemoresistant neoplasms.

Building DNA strands at a high rate that are suitable for data storage. Methods include using DNAzyme and utilizing libraries of pre-prepared oligos. A system for the DNA strand synthesis includes: a DNA symbol library comprising a number of single strand oligo symbols; a DNA linker library comprising a first set of single strand oligo linkers and a second set of single strand oligo linkers; and a DNAzyme library comprising a number of DNAzymes. An S1 end of a first DNAzyme is adapted to join the S1 end of a symbol and an S2 end of the first DNAzyme is adapted to join an S2 end of a first linker, and an S1 end of a second DNAzyme is adapted to join an S1 end of a second linker and an S2 end of the second DNAzyme is adapted to join an S2 end of the symbol.

A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.

The invention relates to a composition for treating a patient suffering from a bowel disease associated with chronic inflammations, the composition comprising at least one DNAzyme which specifically inhibits the expression of GATA-3. A further aspect of the invention relates to the use of such a composition as a drug.

The present invention relates to self-phosphorylating deoxyribozymes containing or consisting of the nucleotide sequence: 5-X.sup.1X.sup.2X.sup.3AX.sup.4X.sup.5-R.sup.1-X.sup.6X.sup.7X.sup.8X.sup.9X.sup.10-bp1-helix1-R.sup.2-helix2-bp2-X.sup.11TGACX.sup.12TGGGAX.sup.13-helix3-X.sup.14-R.sup.3-3 (SEQ ID NO. 1) wherein X.sup.1 is G or T; X.sup.2 is G or T; X.sup.3 is A or C; X.sup.4 is G or T; X.sup.5 is A or T; X.sup.6 is G or T or A; X.sup.7 is A or C or G or T; X.sup.8 is A or G or T; X.sup.9 is T or C or A or G; X.sup.10 is A or T or G; X.sup.11 is G or A; X.sup.12 is T or C or G; X.sup.13 is T or G or C; X.sup.14 is G or A or C or T; R.sup.1 represents a nucleotide sequence containing 3 to 30 nucleotides; R.sup.2 represents a nucleotide sequence containing 3 to 30 nucleotides; R.sup.3 represents a nucleotide sequence containing 0 to 30 nucleotides; bp1 and bp2 are nucleotides selected from G, A, C, T, which together form a base pair; helix1, helix2, and helix3 each independently denotes a nucleotide sequence preferably containing 4 or more nucleotides, wherein helix1, helix2, and helix3 together form a triple helical structure. The deoxyribozymes of the present invention may be used for detection of chemiluminescent substrates, or for detection of analytes (ligands) based on chemiluminescent reaction of the substrates catalyzed by the deoxyribozymes.

Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.

Methods and compositions using dnayzme-based GATA3 inhibitors for the treatment of insulin resistance and Type II diabetes, for the stimulation of adipogenesis in vivo, and for the promotion of fat redistribution are disclosed.

XNAzyme compositions featuring nucleotide analogs, wherein the compositions are capable of rapid, inexpensive, sensitive, and accurate nucleic acid detection. The methods, systems, and compositions herein can provide new options for pathogen detection (e.g., virus detection such as but not limited to SARS-CoV-2), disease diagnosis, and genotyping. The XNAzyme compositions of the present invention combine analyte preamplification with X10-23 mediated catalysis to detect particular nucleic acid trigger sequences. The system functions with a detection limit of at least 20 aM (?10 copies/?L). With an assay time of less than an hour, the present invention provides a faster alternative to quantitative real-time PCR used for viral detection.

In the present specification, on the basis of the correlation between prospero homeobox protein 1 (PROX1) and telomerase reverse transcriptase (TERT), a composition for regulating expression of TERT, a method for screening a TERT expression regulator, a composition for diagnosing a TERT expression status, a diagnostic kit, a method for providing information for diagnosis, or a method for providing information for cancer diagnosis are disclosed. Specifically, in one aspect, the PROX1 of the present disclosure may bind to a TERT promoter, in particular a mutant TERT promoter in which base substitution occurs at the ?124 or ?146 bp position to regulate the expression of TERT, and the expression of TERT in non-hepatitis B virus-associated liver cancer can be inhibited specifically among liver cancers.